Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: In the 2019 WHO FOR NEN’S classification NETG3 have been distinguished from poorly differentiated neuroendocrine carcinoma (NEC). They are heterogeneous group concerning prognosis and treatment benefit.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Ruiz G, Graselli J, Golubicki M, Rizzol M,
Keywords: G3 NEN, PD-L1, KRAS, BIOMARKERS,
Introduction: Pancreatic neuroendocrine tumors (pNET) are rare, have a wide range of phenotypes, increase incidence in recent years; which represents a challenge in diagnosis, treatment, and follow-up
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: González Devia D
Authors: Guzman Ruiz Y, Vera Torres A, López Panqueva R, Ardila Duarte G, González Devia D,
Keywords: Pancreatic neuroendocrine tumors, Pancreatic tumor, Prognosis, Neuroendocrine tumor, Gastroenteropancreatic tumor,
Introduction: Classically, the response assessment to systemic treatment is based on RECIST. In PNET treated with antiangiogenic targeted therapy as sunitinib there is no good correlation between response rate and progression free survival (PFS). Choi criteria might be an alternative to RECIST to evaluate the effect of sunitinib in patients with advanced PNET
Conference: 12th Annual ENETSConcerence (2015)
Presenting Author: Solis Hernandez P
Authors: Solis Hernandez M, Calvo-Temprano D, Jiménez-Fonseca P, Faez L, Ruiz A,
Introduction: Sunitinib and everolimus were approved for treatment of progressive PNET based on phase III trial data. However, features that may influence outcome with these antitargets have not been well-established.
Conference: 11th Annual ENETSConcerence (2014)
Presenting Author:
Authors: Jiménez-Fonseca P, Carmona A, Solis M, Faez L, Ruiz A,
Keywords: Sunitinib, pancreatic neuroendocrine tumor, prior treatment, predictive factor,
Introduction: Well-differentiated (WD) pancreatic neuroendocrine tumors (pNET) are uncommon neoplasms and one challenge lies in predicting tumor behavior and managing these patients.
Conference: 11th Annual ENETSConcerence (2014)
Presenting Author:
Authors: Pérez-Casanova L, Serrano T, Navas C, Ruiz N, Gomez A,
Keywords: pancreas, well-differentiated G2,